ReviewFrontiers in immunology2018
Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.
Review in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it, 162 citations in OpenAlex.
- Efficacy of phage therapy in pigs: systematic review and meta-analysis.Journal of animal science · 2021Pooled it
- Inhalable bacteriophage endolysins: a novel therapeutic strategy for drug-resistant bacterial pulmonary infections - a comprehensive review.Annals of medicine · 2026Review
- High-resolution phage-host assignment through key proteins using large language models.Nature communications · 2026Article
- Identification and analysis of the crucial holin domain and sites and the bactericidal activity of a holin-endolysin lysis cassette from phage PZL-Ah152 againstJournal of virology · 2026Article
- Antimicrobial Resistance: How Can We Overcome the Problem?Antibiotics (Basel, Switzerland) · 2026Review
- Translational barriers to phage endolysin deployment for antimicrobial resistance control in Africa.Frontiers in antibiotics · 2026Review
- The New SH3b_T Domain Increases the Structural and Functional Variability Among SH3b-Like CBDs from Staphylococcal Phage Endolysins.Probiotics and antimicrobial proteins · 2025Article
- Engineering a Potent Anti-MRSA Agent: The Development and Characterization of Chimeric Endolysin ZAM-MSC.Iranian biomedical journal · 2025Article
- In Vitro Antibacterial Efficacy of Recombinant Phage-Derived Endolysin LysTAC1 Against Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Phage-induced protection against lethal bacterial reinfection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Biosimilars Targeting Pathogens: A Comprehensive Review of Their Role in Bacterial, Fungal, Parasitic, and Viral Infections.Pharmaceutics · 2025Review
- Structure, Function, and Regulation of LytA: TheMicroorganisms · 2025Review
- Novel Anti-Microbial/Anti-Inflammatory Combination Improves Clinical Outcome of Bacillus cereus Endophthalmitis.Investigative ophthalmology & visual science · 2025Article
- InactivatedFrontiers in immunology · 2025Article
- Endolysins and membrane-active peptides: innovative engineering strategies against gram-negative bacteria.Frontiers in microbiology · 2025Review
- Biotherapeutic potential of different fractions of cell-free supernatants fromFrontiers in cellular and infection microbiology · 2025Article
- A comparative guide to expression systems for phage lysin production.Essays in biochemistry · 2024Review
- Characterization and Potential Application of Phage vB_PmuM_CFP3 for Phage Therapy Against AvianAnimals : an open access journal from MDPI · 2024Article
- Discovery and characterization of a novel LysinB from F2 sub-cluster mycobacteriophage RitSun.Scientific reports · 2024Article
- Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections.Journal of biomedical science · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower respiratory tract infections and tuberculosis are responsible for the death of about 4.5 million people each year and are the main causes of mortality in children under 5 years of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.